As evidenced most recently by Allergan plc's purchase of Tobira Therapeutics Inc. and Akarna Therapeutics Ltd., nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are getting a lot of love from the pharma industry these days, with good reason. (See BioWorld Today, Sept. 21, 2016.)